MagicMed Industries

MagicMed Industries was a private biotechnology company focused on discovering and developing novel psychedelic-derived small molecules. Its core asset was the "Psybrary," a library of derivative compounds based on classic psychedelics such as psilocybin and N,N-dimethyltryptamine, designed to generate patentable next-generation neuropsychiatric therapeutics. The company positioned itself as a discovery and intellectual-property platform that could partner with pharmaceutical companies to advance selected candidates. In September 2021, MagicMed was acquired by Enveric Biosciences in an all-stock transaction, and its assets and platform were integrated into Enveric's broader pipeline in oncology supportive care and central nervous system indications.